References:
- Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past,
present, and future. J Clin Invest . 2006;116(11):2843-2854.
doi:10.1172/JCI29894
- Benamer HT, Bredan A. The epidemiology of myasthenia gravis in Arab
countries: a systematic review. Muscle Nerve .
2015;51(1):144-145. doi:10.1002/mus.24350
- Sasi S, Yassin MA, Fadul AM. A Case of Acquired von Willebrand Disease
Secondary to Myeloproliferative Neoplasm. Case Rep Oncol .
2020;13(2):733-737. Published 2020 Jun 26. doi:10.1159/000507883
- Turkina A, Wang J, Mathews V, Saydam G, Jung CW, Al Hashmi HH, Yassin
M, Le Clanche S, Miljkovic D, Slader C, Hughes TP. TARGET: a survey of
real‐world management of chronic myeloid leukaemia across 33
countries. British Journal of Haematology. 2020 Mar 30
- Yassin MA, Taher A, Mathews V, Hou HA, Shamsi T, Tuğlular TF, Xiao Z,
Kim SJ, Depei W, Li J, Rippin G. MERGE: a multinational, multicenter
observational registry for myeloproliferative neoplasms in Asia,
including Middle East, Turkey, and Algeria. Cancer Medicine. 2020 Apr
30.
- Al-Dewik N, Ben-Omran T, Zayed H, Trujillano D, Kishore S, Rolfs A,
Yassin MA. Clinical exome sequencing unravels new disease-causing
mutations in the myeloproliferative neoplasms: a pilot study in
patients from the state of Qatar. Gene. 2019 Mar 20;689:34-42.
- Dührsen U, Augener W, Zwingers T, Brittinger G. Spectrum and frequency
of autoimmune derangements in lymphoproliferative disorders: analysis
of 637 cases and comparison with myeloproliferative diseases. Br
J Haematol . 1987;67(2):235-239.
doi:10.1111/j.1365-2141.1987.tb02333.x
- Kumar P, Jain P, Menon H, Purvish P. Chronic myeloid leukemia
presenting as paraneoplastic ocular myasthenia gravis. Ann
Oncol . 2007;18(4):804-805. doi:10.1093/annonc/mdm010
- Sharma N, Dua H, Rosha D. Chronic myeloid leukemia with an unusual
paraneoplastic syndrome. J Assoc Physicians India .
2012;60:47-48.
- Eivaz-Mohammadi S, Gonzalez-Ibarra F, Hekmatjou H, Mikkilineni R,
Patel A, Syed AK. Myasthenia gravis-like syndrome presenting as a
component of the paraneoplastic syndrome of lung adenocarcinoma in a
nonsmoker. Case Rep Oncol Med . 2014;2014:703828.
doi:10.1155/2014/703828
- Lengfelder E, Berger U, Hehlmann R. Interferon alpha in the treatment
of polycythemia vera. Ann Hematol. 2000 Mar;79(3):103-9. doi:
10.1007/s002770050563. PMID: 10803930.
- Bolay H, Karabudak R, Aybay C, Candemir H, Varli K, Imir T, Kansu E.
Alpha interferon treatment in myasthenia gravis: effects on natural
killer cell activity. J Neuroimmunol. 1998 Mar 1;82(2):109-15. doi:
10.1016/s0165-5728(97)00146-x. PMID: 9585806.
- Gurtubay IG, Morales G, Aréchaga O, Gállego J. Development of
myasthenia gravis after interferon alpha therapy. Electromyogr Clin
Neurophysiol. 1999 Mar;39(2):75-8. PMID: 10207675.
- Batocchi AP, Evoli A, Servidei S, Palmisani MT, Apollo F, Tonali P.
Myasthenia gravis during interferon alfa therapy. Neurology. 1995
Feb;45(2):382-3. doi: 10.1212/wnl.45.2.382. PMID: 7854543.
Figure Legends:Fig. 1. Ultrasound abdomen of Patient 1 showing massive splenomegaly
Fig. 2. Ultrasound abdomen of Patient 2 showing massive splenomegaly